Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3033802 | 0.93 | EPHX2 (0.59) | EPHX2HDAC1HDAC6ROCK2OPRM1 | |
| SCHEMBL3039558 | 0.87 | EPHX2 (0.61) | EPHX2HDAC1HDAC6ROCK2ROCK1 | |
| SCHEMBL3036133 | 0.87 | EPHX2 (0.60) | EPHX2OPRM1OPRD1OPRK1CYP3A4 | |
| SCHEMBL3028889 | 0.86 | EPHX2 (0.59) | EPHX2HDAC1HDAC6ROCK2OPRM1 | |
| SCHEMBL2908128 | 0.86 | EPHX2 (0.58) | EPHX2HDAC1HDAC6ROCK2OPRM1 | |
| SCHEMBL2903808 | 0.85 | EPHX2 (0.57) | EPHX2ROCK2ROCK1OPRM1OPRD1 | |
| SCHEMBL2906220 | 0.84 | EPHX2 (0.72) | EPHX2OPRM1OPRD1OPRK1CYP3A4 | |
| SCHEMBL2906992 | 0.83 | EPHX2 (0.55) | EPHX2ROCK2ROCK1OPRM1OPRD1 | |
| SCHEMBL2908406 | 0.82 | EPHX2 (0.54) | EPHX2CYP3A4LMNAMAPK1NLRP1 | |
| SCHEMBL2907081 | 0.82 | EPHX2 (0.53) | EPHX2ROCK2P2RX7LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210655-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-08-19 | — | — | US | claimed |
| US-20100210655-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-08-19 | — | — | US | disclosed |
| US-20100210655-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-08-19 | — | — | US | disclosed |
| US-20100210655-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-08-19 | — | — | US | disclosed |
| WO-2009049154-A1 | NOVEL sEH INHIBITORS AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210655-A1 | NOVEL sEH INHIBITORS AND THEIR USE | EPHX1, NCEH1, FAH | EPHX2 5/4885HDAC1 641/4885HDAC6 2367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.